Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo

Margaret O. Sowell, Nitai Mukhopadhyay, Patrizia Cavazzoni, Sudha Shankar, Helmut O. Steinberg, Alan Breier, Charles M. Beasley, Jamie Dananberg

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

The goal of this study was to evaluate the effect of olanzapine or risperidone treatment on β-cell function in healthy volunteers. Subjects were randomly assigned to single-blind therapy with olanzapine (10 mg/d; n = 17), risperidone (4 mg/d; n = 13), or placebo (n = 18) for 15-17 d. Insulin secretion was quantitatively assessed at baseline and the end of the study period using the hyperglycemic clamp. Weight increased significantly (P <0.01) in the olanzapine (2.8 ± 1.7 kg) and risperidone (3.1 ± 2.1 kg) treatment groups. An increase (∼25%) in the insulin response to hyperglycemia and a decrease (∼18%) in the insulin sensitivity index were observed after treatment with olanzapine and risperidone. The change in insulin response was correlated (r = 0.5576; P = 0.019) with a change in body mass index. When the impact of weight change was accounted for by multivariate regression analyses, no significant change in insulin response or insulin sensitivity was detected after treatment with olanzapine or risperidone. We found no evidence that treatment of healthy volunteers with olanzapine or risperidone decreased the insulin secretory response to a prolonged hyperglycemic challenge. The results of this study do not support the hypothesis that alanzapine or risperidone directly impair pancreatic β-cell function.

Original languageEnglish (US)
Pages (from-to)2918-2923
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume87
Issue number6
DOIs
StatePublished - 2002

Fingerprint

olanzapine
Risperidone
Clamping devices
Placebos
Insulin
Insulin Resistance
Healthy Volunteers
Therapeutics
Weights and Measures
Hyperglycemia
Body Mass Index
Multivariate Analysis
Regression Analysis

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. / Sowell, Margaret O.; Mukhopadhyay, Nitai; Cavazzoni, Patrizia; Shankar, Sudha; Steinberg, Helmut O.; Breier, Alan; Beasley, Charles M.; Dananberg, Jamie.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 87, No. 6, 2002, p. 2918-2923.

Research output: Contribution to journalArticle

Sowell, Margaret O. ; Mukhopadhyay, Nitai ; Cavazzoni, Patrizia ; Shankar, Sudha ; Steinberg, Helmut O. ; Breier, Alan ; Beasley, Charles M. ; Dananberg, Jamie. / Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. In: Journal of Clinical Endocrinology and Metabolism. 2002 ; Vol. 87, No. 6. pp. 2918-2923.
@article{a073fe5e6aac4a5fac579d98b84b832e,
title = "Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo",
abstract = "The goal of this study was to evaluate the effect of olanzapine or risperidone treatment on β-cell function in healthy volunteers. Subjects were randomly assigned to single-blind therapy with olanzapine (10 mg/d; n = 17), risperidone (4 mg/d; n = 13), or placebo (n = 18) for 15-17 d. Insulin secretion was quantitatively assessed at baseline and the end of the study period using the hyperglycemic clamp. Weight increased significantly (P <0.01) in the olanzapine (2.8 ± 1.7 kg) and risperidone (3.1 ± 2.1 kg) treatment groups. An increase (∼25{\%}) in the insulin response to hyperglycemia and a decrease (∼18{\%}) in the insulin sensitivity index were observed after treatment with olanzapine and risperidone. The change in insulin response was correlated (r = 0.5576; P = 0.019) with a change in body mass index. When the impact of weight change was accounted for by multivariate regression analyses, no significant change in insulin response or insulin sensitivity was detected after treatment with olanzapine or risperidone. We found no evidence that treatment of healthy volunteers with olanzapine or risperidone decreased the insulin secretory response to a prolonged hyperglycemic challenge. The results of this study do not support the hypothesis that alanzapine or risperidone directly impair pancreatic β-cell function.",
author = "Sowell, {Margaret O.} and Nitai Mukhopadhyay and Patrizia Cavazzoni and Sudha Shankar and Steinberg, {Helmut O.} and Alan Breier and Beasley, {Charles M.} and Jamie Dananberg",
year = "2002",
doi = "10.1210/jc.87.6.2918",
language = "English (US)",
volume = "87",
pages = "2918--2923",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo

AU - Sowell, Margaret O.

AU - Mukhopadhyay, Nitai

AU - Cavazzoni, Patrizia

AU - Shankar, Sudha

AU - Steinberg, Helmut O.

AU - Breier, Alan

AU - Beasley, Charles M.

AU - Dananberg, Jamie

PY - 2002

Y1 - 2002

N2 - The goal of this study was to evaluate the effect of olanzapine or risperidone treatment on β-cell function in healthy volunteers. Subjects were randomly assigned to single-blind therapy with olanzapine (10 mg/d; n = 17), risperidone (4 mg/d; n = 13), or placebo (n = 18) for 15-17 d. Insulin secretion was quantitatively assessed at baseline and the end of the study period using the hyperglycemic clamp. Weight increased significantly (P <0.01) in the olanzapine (2.8 ± 1.7 kg) and risperidone (3.1 ± 2.1 kg) treatment groups. An increase (∼25%) in the insulin response to hyperglycemia and a decrease (∼18%) in the insulin sensitivity index were observed after treatment with olanzapine and risperidone. The change in insulin response was correlated (r = 0.5576; P = 0.019) with a change in body mass index. When the impact of weight change was accounted for by multivariate regression analyses, no significant change in insulin response or insulin sensitivity was detected after treatment with olanzapine or risperidone. We found no evidence that treatment of healthy volunteers with olanzapine or risperidone decreased the insulin secretory response to a prolonged hyperglycemic challenge. The results of this study do not support the hypothesis that alanzapine or risperidone directly impair pancreatic β-cell function.

AB - The goal of this study was to evaluate the effect of olanzapine or risperidone treatment on β-cell function in healthy volunteers. Subjects were randomly assigned to single-blind therapy with olanzapine (10 mg/d; n = 17), risperidone (4 mg/d; n = 13), or placebo (n = 18) for 15-17 d. Insulin secretion was quantitatively assessed at baseline and the end of the study period using the hyperglycemic clamp. Weight increased significantly (P <0.01) in the olanzapine (2.8 ± 1.7 kg) and risperidone (3.1 ± 2.1 kg) treatment groups. An increase (∼25%) in the insulin response to hyperglycemia and a decrease (∼18%) in the insulin sensitivity index were observed after treatment with olanzapine and risperidone. The change in insulin response was correlated (r = 0.5576; P = 0.019) with a change in body mass index. When the impact of weight change was accounted for by multivariate regression analyses, no significant change in insulin response or insulin sensitivity was detected after treatment with olanzapine or risperidone. We found no evidence that treatment of healthy volunteers with olanzapine or risperidone decreased the insulin secretory response to a prolonged hyperglycemic challenge. The results of this study do not support the hypothesis that alanzapine or risperidone directly impair pancreatic β-cell function.

UR - http://www.scopus.com/inward/record.url?scp=0036078820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036078820&partnerID=8YFLogxK

U2 - 10.1210/jc.87.6.2918

DO - 10.1210/jc.87.6.2918

M3 - Article

C2 - 12050274

AN - SCOPUS:0036078820

VL - 87

SP - 2918

EP - 2923

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -